Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma.
Journal
Advances in anatomic pathology
ISSN: 1533-4031
Titre abrégé: Adv Anat Pathol
Pays: United States
ID NLM: 9435676
Informations de publication
Date de publication:
01 May 2022
01 May 2022
Historique:
pubmed:
12
3
2022
medline:
12
4
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
The World Health Organization (WHO) recommends grading of clear cell renal cell carcinoma (RCC) and papillary RCC using the WHO/International Society of Urological Pathology (ISUP) grade, which is primarily based on nuclear features. As the spectrum of RCC continues to evolve, with more recently described subtypes in the past decade, literature evidence on grading these subtypes is limited or not available for some tumor types. Herein, we outline a pragmatic approach to the topic of grading RCC, dividing the contemporarily described RCC subtypes into 7 categories based on the potential clinical applicability of grading as a useful prognostic parameter: (1) RCC subtypes that are reasonably validated and recommended for WHO/ISUP grading; (2) RCC subtypes where WHO/ISUP is not applicable; (3) RCC subtypes where WHO/ISUP grading is potentially clinically useful; (4) inherently aggressive RCC subtypes where histologic classification itself confers an aggressive biologic potential; (5) renal epithelial tumors where WHO/ISUP grading provides potentially misleading prognostic implication; (6) renal epithelial neoplasms where low WHO/ISUP grade features are a prerequisite for accurate histologic classification; and (7) renal epithelial neoplasms with no or limited data on grading or incomplete understanding of the biologic potential. Our aim in outlining this approach is 2-fold: (a) identify the gaps in understanding and application of grading in RCC subtypes so that researchers in the field may perform additional studies on the basis of which the important pathologic function of assignment of grade may be recommended to be performed as a meaningful exercise across a wider spectrum of RCC; and (b) to provide guidance in the interim to surgical pathologists in terms of providing clinically useful grading information in RCC based on currently available clinicopathologic information.
Identifiants
pubmed: 35275846
doi: 10.1097/PAP.0000000000000341
pii: 00125480-202205000-00001
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-130Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Vinay K, Abbas AK, Aster JC. Robbins & Cotran Basic Pathology, 10th ed. Philadelphia, PA: Elsevier Saunders; 2021.
Hand JR, Broders AC. Carcinoma of the kidney: the degree of malignancy in relation to factors bearing on prognosis. J Urol. 1932;28:199–216.
Delahunt B, Eble JN, Egevad L, et al. Grading of renal cell carcinoma. Histopathology. 2019;74:4–17.
Rice-Stitt T, Valencia-Guerrero A, Cornejo KM, et al. Updates in histologic grading of urologic neoplasms. Arch Pathol Lab Med. 2020;144:335–343.
Novara G, Martignoni G, Artibani W, et al. Grading systems in renal cell carcinoma. J Urol. 2007;177:430–436.
Myers GH Jr, Fehrenbaker LG, Kelalis PP. Prognostic significance of renal vein invasion by hypernephroma. J Urol. 1968;100:420–423.
Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–663.
Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol. 2011;35:1134–1139.
Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490–1504.
Moch H, Humphrey PA, Ulbright TM, Reuter VE, eds. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
Meskawi M, Sun M, Trinh QD, et al. A review of integrated staging systems for renal cell carcinoma. Eur Urol. 2012;62:303–314.
Lohse CM, Gupta S, Cheville JC. Outcome prediction for patients with renal cell carcinoma. Semin Diagn Pathol. 2015;32:172–183.
Srigley JR, Paner GP, Zhou M, et al. Protocol for the examination of resection specimens from patients with invasive carcinoma of renal tubular origin; 2020. Available at: www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates . Accessed December 1, 2021.
Delahunt B, Srigley JR, Judge MJ, et al. Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2019;74:377–390.
Trpkov K, Williamson SR, Gill AJ, et al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34:1167–1184.
Trpkov K, Hes O. New and emerging renal entities: a perspective post-WHO 2016 classification. Histopathology. 2019;74:31–59.
Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37:1469–1489.
Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol. 2007;31:957–960.
Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol. 2010;34:1233–1240.
Ohashi R, Martignoni G, Hartmann A, et al. Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Arch. 2020;476:409–418.
Standards and Datasets for Reporting Cancers. Dataset for histopathological reporting of adult renal parenchyma neoplasms; 2017. Available at: www.rcpath.org/ . Accessed December 1, 2021.
Amin MB, Paner GP, Alvarado-Cabrero I, et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol. 2008;32:1822–1834.
Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11:71–77.
Moch H, Gasser T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604–614.
Paner GP, Amin MB, Moch H, et al. Moch H, Humphrey PA, Ulbright TM, Reuter VE. Chromophobe renal cell carcinoma. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edition. Geneva, Switzerland: WHO Press; 2016:27–28.
Przybycin CG, Cronin AM, Darvishian F, et al. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol. 2011;35:962–970.
Banach BS, Paner GP. Chromophobe renal cell carcinoma with high-grade features: can we disregard the grade? AJSP Rev Rep. 2017;22:282–285.
Avulova S, Cheville JC, Lohse CM, et al. Grading chromophobe renal cell carcinoma: evidence for a four-tiered classification incorporating coagulative tumor necrosis. Eur Urol. 2021;79:225–231.
Cheville JC, Lohse CM, Sukov WR, et al. Chromophobe renal cell carcinoma: the impact of tumor grade on outcome. Am J Surg Pathol. 2012;36:851–856.
Finley DS, Shuch B, Said JW, et al. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. J Urol. 2011;186:2168–2174.
Weinzierl EP, Thong AE, McKenney JK, et al. Relating prognosis in chromophobe renal cell carcinoma to the chromophobe tumor grading system. Korean J Urol. 2014;55:239–244.
Alimchandani M, Niera de Paz C, Williams S, et al. Aggressive variants of chromophobe renal cell carcinoma: importance of recognition and grading. Mod Pathol. 2013;26:192A.
Sali AP, Bahirwade GK, Bakshi G, et al. Application and comparison of Fuhrman nuclear grading system with the novel tumor grading system for chromophobe renal cell carcinoma and its correlation with disease-specific events. Indian J Urol. 2021;37:147–152.
Lohse CM, Blute ML, Zincke H, et al. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2042 patients. Am J Clin Pathol. 2002;118:877–886.
Richard PO, Jewett MA, Bhatt JR, et al. Active surveillance for renal neoplasms with oncocytic features is safe. J Urol. 2016;195:581–586.
Derweesh IH. Percutaneous biopsy of renal masses-when is it necessary? J Urol. 2016;195:542–543.
Sokhi HK, Mok WY, Patel U. Stage T3a renal cell carcinoma: staging accuracy of CT for sinus fat, perinephric fat or renal vein invasion. Br J Radiol. 2015;88:20140504.
Bradley AJ, MacDonald L, Whiteside S, et al. Accuracy of preoperative CT T staging of renal cell carcinoma: which features predict advanced stage? Clin Radiol. 2015;70:822–829.
Ohashi R, Hartmann A, Martignoni G, et al. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That’s the Question!. Eur Urol. 2021;80:e17–e18.
Avulova S, Cheville JC, Lohse CM, et al. Reply to Riuko Ohashi, Arndt Hartmann, Holger Moch, and Guido Martignoni’s Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That’s the Question!. Eur Urol. 2021;80:e19.
Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31:1149–1160.
Liu N, Gan W, Qu F, et al. Does the Fuhrman or World Health Organization/International Society of Urological Pathology Grading System apply to the Xp11.2 translocation renal cell carcinoma?: a 10-year single-center study. Am J Pathol. 2018;188:929–936.
Qu Y, Zhao R, Wang H, et al. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma. Sci Rep. 2016;6:23594.
Calio A, Brunelli M, Segala D, et al. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. Pathology. 2020;52:297–309.
Lee HJ, Shin DH, Kim SY, et al. TFE3 translocation and protein expression in renal cell carcinoma are correlated with poor prognosis. Histopathology. 2018;73:758–766.
Gandhi JS, Malik F, Amin MB, et al. MiT family translocation renal cell carcinomas: a 15th anniversary update. Histol Histopathol. 2020;35:125–136.
Xia QY, Wang XT, Fang R, et al. Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum. Am J Surg Pathol. 2020;44:477–489.
Argani P, Reuter VE, Zhang L, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40:1484–1495.
Williamson SR, Grignon DJ, Cheng L, et al. Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis? Am J Surg Pathol. 2017;41:287–298.
Gupta S, Johnson SH, Vasmatzis G, et al. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol. 2017;30:998–1012.
Gupta S, Argani P, Jungbluth AA, et al. TFEB expression profiling in renal cell carcinomas: clinicopathologic correlations. Am J Surg Pathol. 2019;43:1445–1461.
Williamson SR, Eble JN, Amin MB, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol. 2015;28:80–94.
Gill AJ, Pachter NS, Chou A, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol. 2011;35:1578–1585.
Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38:1588–1602.
Fuchs TL, Maclean F, Turchini J, et al. Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Mod Pathol. 2021. [Epub ahead of print].
Dhillon J, Amin MB, Selbs E, et al. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol. 2009;33:44–49.
Hatayama T, Sekino Y, Shikuma H, et al. Case of renal mucinous tubular and spindle cell carcinoma with high nuclear grade. IJU Case Rep. 2019;2:193–196.
Ged Y, Chen YB, Knezevic A, et al. Mucinous tubular and spindle-cell carcinoma of the kidney: clinical features, genomic profiles, and treatment outcomes. Clin Genitourin Cancer. 2019;17:268–274.e1.
Yang C, Cimera RS, Aryeequaye R, et al. Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. Mod Pathol. 2021;34:445–456.
Sadimin ET, Chen YB, Wang L, et al. Chromosomal abnormalities of high-grade mucinous tubular and spindle cell carcinoma of the kidney. Histopathology. 2017;71:719–724.
Kwon R, Argani P, Epstein JI, et al. Contemporary characterization and recategorization of adult unclassified renal cell carcinoma. Am J Surg Pathol. 2021;45:450–462.
Ursani NA, Robertson AR, Schieman SM, et al. Mucinous tubular and spindle cell carcinoma of kidney without sarcomatoid change showing metastases to liver and retroperitoneal lymph node. Hum Pathol. 2011;42:444–448.
Hakimi AA, Tickoo SK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol. 2015;28:845–853.
DiNatale RG, Gorelick AN, Makarov V, et al. Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: an emerging entity with variable clinical course. Eur Urol Focus. 2021;7:381–389.
Shah RB, Stohr BA, Tu ZJ, et al. “Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol. 2020;44:571–581.
Lopez-Beltran A, Kirkali Z, Montironi R, et al. Unclassified renal cell carcinoma: a report of 56 cases. BJU Int. 2012;110:786–793.
Akgul M, Cheng L. Immunophenotypic and pathologic heterogeneity of unclassified renal cell carcinoma: a study of 300 cases. Hum Pathol. 2020;102:70–78.
Trpkov K, Hes O, Bonert M, et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40:60–71.
Smith SC, Sirohi D, Ohe C, et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. Histopathology. 2017;71:42–52.
Chen YB, Mirsadraei L, Jayakumaran G, et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43:121–131.
Trpkov K, Williamson SR, Gao Y, et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 2019;75:174–184.
Kuroda N, Trpkov K, Gao Y, et al. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol. 2020;33:2564–2579.
Smith SC, Trpkov K, Chen YB, et al. Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2016;40:1457–1472.
Ohe C, Smith SC, Sirohi D, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2018;42:279–292.
Lau HD, Chan E, Fan AC, et al. A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol. 2020;44:98–110.
Trpkov K, Hes O, Agaimy A, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol. 2016;40:865–875.
Merino MJ, Torres-Cabala C, Pinto P, et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31:1578–1585.
Hamza A, Sirohi D, Smith SC, et al. Low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma: an update on biologic potential, morphologic spectrum, and differential diagnosis with other low-grade oncocytic tumors. Adv Anat Pathol. 2021;28:396–407.
Gupta R, Billis A, Shah RB, et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol. 2012;36:1265–1278.
Rao P, Tannir NM, Tamboli P. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol. 2012;36:583–588.
Agaimy A, Cheng L, Egevad L, et al. Rhabdoid and undifferentiated phenotype in renal cell carcinoma: analysis of 32 cases indicating a distinctive common pathway of dedifferentiation frequently associated with SWI/SNF complex deficiency. Am J Surg Pathol. 2017;41:253–262.
Sirohi D, Smith SC, Ohe C, et al. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. Hum Pathol. 2017;67:134–145.
Amin MB, Smith SC, Agaimy A, et al. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol. 2014;38:871–874.
May M, Ficarra V, Shariat SF, et al. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model. J Urol. 2013;190:458–463.
Sui W, Matulay JT, Robins DJ, et al. Collecting duct carcinoma of the kidney: disease characteristics and treatment outcomes from the National Cancer Database. Urol Oncol. 2017;35:540.e13–540.e18.
Amin MB, MacLennan GT, Gupta R, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol. 2009;33:384–392.
Yang XJ, Zhou M, Hes O, et al. Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol. 2008;32:177–187.
Alexiev BA, Drachenberg CB. Tubulocystic carcinoma of the kidney: a histologic, immunohistochemical, and ultrastructural study. Virchows Arch. 2013;462:575–581.
Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30:141–153.
Przybycin CG, Harper HL, Reynolds JP, et al. Acquired cystic disease-associated renal cell carcinoma (ACD-RCC): a multiinstitutional study of 40 cases with clinical follow-up. Am J Surg Pathol. 2018;42:1156–1165.
Kondo T, Sasa N, Yamada H, et al. Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: central pathology results according to the 2016 WHO classification in a multi-institutional study. Pathol Int. 2018;68:543–549.
Kondo T, Sassa N, Yamada H, et al. Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. Pathology. 2021;53:720–727.
Kojima F, Gandhi JS, Matsuzaki I, et al. Comprehensive clinicopathologic analyses of acquired cystic disease-associated renal cell carcinoma with focus on adverse prognostic factors and metastatic lesions. Am J Surg Pathol. 2020;44:1031–1039.
Trpkov K, Abou-Ouf H, Hes O, et al. Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol. 2017;41:1299–1308.
Palsgrove DN, Li Y, Pratilas CA, et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol. 2018;42:1166–1181.
He H, Trpkov K, Martinek P, et al. “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch. 2018;473:725–738.
Mihaela F, Zoran G, Kiril T, et al. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Mod Pathol. 2022;35:344–351.
Wang KL, Weinrach DM, Luan C, et al. Renal papillary adenoma—a putative precursor of papillary renal cell carcinoma. Hum Pathol. 2007;38:239–246.
Chen S, Jin B, Xu L, et al. Cystic renal cell carcinoma: a report of 67 cases including 4 cases with concurrent renal cell carcinoma. BMC Urol. 2014;14:87.
Li T, Chen J, Jiang Y, et al. Multilocular cystic renal cell neoplasm of low malignant potential: a series of 76 cases. Clin Genitourin Cancer. 2016;14:e553–e557.
Suzigan S, Lopez-Beltran A, Montironi R, et al. Multilocular cystic renal cell carcinoma: a report of 45 cases of a kidney tumor of low malignant potential. Am J Clin Pathol. 2006;125:217–222.
Williamson SR, Eble JN, Cheng L, et al. Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. Mod Pathol. 2013;26:697–708.
Williamson SR. Clear cell papillary renal cell carcinoma: an update after 15 years. Pathology. 2021;53:109–119.
Thompson RH, Hill JR, Babayev Y, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009;182:41–45.
Umbreit EC, Shimko MS, Childs MA, et al. Metastatic potential of a renal mass according to original tumour size at presentation. BJU Int. 2012;109:190–194; discussion 194.
Guethmundsson E, Hellborg H, Lundstam S, et al. Swedish Kidney Cancer Quality Register Group. Metastatic potential in renal cell carcinomas </=7 cm: Swedish Kidney Cancer Quality Register data. Eur Urol. 2011;60:975–982.
Carbonara U, Simone G, Minervini A, et al. Robotic-assisted partial nephrectomy for “very small” (<2 cm) renal mass: results of a multicenter contemporary cohort. Eur Urol Focus. 2021;7:1115–1120.
Yang C, Shuch B, Kluger H, et al. High WHO/ISUP grade and unfavorable architecture, rather than typing of papillary renal cell carcinoma, may be associated with worse prognosis. Am J Surg Pathol. 2020;44:582–593.
Paner GP, Cimadamore A, Darrell CM, et al. Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? Diagn Histopathol. 2020;26:320–329.
Diolombi ML, Cheng L, Argani P, et al. Do clear cell papillary renal cell carcinomas have malignant potential? Am J Surg Pathol. 2015;39:1621–1634.
Aron M, Chang E, Herrera L, et al. Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor. Am J Surg Pathol. 2015;39:873–888.
Williamson SR, Gupta NS, Eble JN, et al. Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: combined morphologic, immunohistochemical, and cytogenetic analysis. Am J Surg Pathol. 2015;39:1502–1510.
Dhakal HP, McKenney JK, Khor LY, et al. Renal neoplasms with overlapping features of clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma: a clinicopathologic study of 37 cases from a single institution. Am J Surg Pathol. 2016;40:141–154.